03.06.20 ijBio Index

ijBio: Farm Involved ijBio-Index:

June,3 2020:

AstraZeneca (AZN) $55 (+0.5%)

Inovio (INO) $12,4 (-12.3%)

Moderna (MRNA) $60 (+0.3%)

Abbot (ABT) $91,4 (-1.3%)

Gilead (GILD). $74,4 (+1.6%)

Adaptive (ADPT) $39,6 (+2%)

CytoDyn (CYDY) $2,9 (-2%)

AbbVie (ABBV) $90,6 (-0.3%)

Deciphera (DCPH) $56,8 (-4.3%)

Sorrento (SRNE) $4,1 (-13,2%)

At close 03.06.20=490,8 (-0,34%)

previous day <---> next day

At close 02.06.20=492,5 (-1,1%)

At close 01.06.20= 498 (-0,62%)

At close 29.05.20= 501,4 (+3,8%)

Index was launched 26.05.20= 504

--

Portfolio News:

Why Gilead's Coronavirus Drug Could Be A Mega Blockbuster: Analyst

Arcus Biosciences to Participate in the Goldman Sachs 41st Annual Global Healthcare Conference Webcast

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sorrento Therapeutics, Inc. - SRNE

SRNE ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 27, 2020 in the Class Action Filed on Behalf of Sorrento Therapeutics, Inc. Limited Shareholders

Why Inovio Pharmaceuticals Stock Sank Today

NYT: Trump identifies five drugmakers most likely to produce a viable COVID-19 vaccine

SRNE Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Sorrento Therapeutics, Inc and Encourages Investors to Contact the Firm

Watch out: This is the age where you should definitely stop trading stocks

Coronavirus update: Global death toll tops 380,000 as Brazil records biggest one-day increase since start of outbreak

CLASS ACTION UPDATE for BIDU, SRNE and CLNY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Emergent BioSolutions Picks Up a "Warp Speed" Contract to Manufacture Coronavirus Vaccines

Analyst Sounds the Valuation Alarm Bell on Inovio’s Hot Stock

IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sorrento Therapeutics, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm

Gilead Sciences Upgraded on Potential Virus Drug Sales

Sanofi to run consultations over restart of hydroxychloroquine trials

Vaccine group plans advance market agreement for COVID-19 vaccines

N.Y. Deaths at 10-Week Low; WHO Resumes Drug Trial: Virus Update

Moderna’s New Vaccine Business Could Be Bigger Than COVID, Says 5-Star Analyst

U.S. IPO market to reopen with a bang as the biggest deal of the year takes off

Ad

Neck RelaxThis Neck Relax Device Is Selling Like Crazy In Russia

Wednesday Morning Market Highlights

Coronavirus update: Global death toll tops 380,000 as Brazil records biggest one-day increase since start of outbreak

Gilead's remdesivir could see $7 billion in annual sales on stockpiling boost: analyst

Brazil to start testing Oxford vaccine against the coronavirus this month

Moderna Shows Off Its Biotech Science Projects

Is AbbVie (ABBV) Stock Undervalued Right Now?

Buy this, not that — 5 stocks to trade into now and 5 to avoid

Why Sorrento Therapeutics Shares Are Tumbling Today

Why Moderna Shares Rose 33.7% in May

Biotech Stock Roundup: GILD's Coronavirus Drug Update, NTLA-REGN Deal & More

The Zacks Analyst Blog Highlights: Pfizer, Comcast, salesforce.com, Costco Wholesale and BHP Group

Gilead Upgraded With Covid Sales Seen Reaching $7.7 Billion

Buy Gilead Stock Because Remdesivir Is Worth Billions in Sales, Analyst Says

Increased Earnings Estimates Seen for AbbVie (ABBV): Can It Move Higher?

Gilead's stock upgraded on high hopes for remdesivir revenue

AbbVie to Present at the Virtual Goldman Sachs 41st Annual Global Healthcare Conference

MORE NEWS>>>

Advertise With Us

© 2020 Verizon Media. All rights reserved.

Data DisclaimerHelpSuggestions

• Privacy (Updated)About Our AdsTerms (Updated)Sitemap